Cameron Turtle sold $1.3M of Spyre Therapeutics (SYRE)

Executed Oct 1, disclosed Oct 3, 1 day later.

Value, as filed

$1.3M

14,300 sh across 4 lots

Executed

Oct 1

the trade date, as filed

Disclosed

Oct 3

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Cameron Turtle Chief Executive Officer profile →

Cameron Turtle (Chief Executive Officer) filed 11 Form 4 reports in the trailing twelve months (0 purchases, 11 sales), most often in Spyre Therapeutics, Inc. (SYRE). The largest single filing was $1.4M of SYRE (14,184 sh across 3 lots, as filed), executed Aug 3.

The name

SYRE

Spyre Therapeutics, Inc. SYRE · Healthcare · 32 filings in 24 months ticker →

Healthcare · Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Cameron Turtle in SYRE

SYRESALE Spyre Therapeutics, Inc. $1.3M
14,600 sh across 3 lots
Exec Sep 1
Filed Sep 3 · 9:33 PM ET SYRESALE Spyre Therapeutics, Inc. $1.4M
14,184 sh across 3 lots
Exec Aug 3
Filed Aug 5 · 9:31 PM ET SYRESALE Spyre Therapeutics, Inc. $1.3M
14,410 sh across 2 lots
Exec Jul 1
Filed Jul 2 · 9:32 PM ET SYRESALE Spyre Therapeutics, Inc. $1.1M
15,000 sh across 3 lots
Exec Jun 1
Filed Jun 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. $976K
13,700 sh across 4 lots
Exec May 1
Filed May 1 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. $740K
15,000 sh across 2 lots
Exec Apr 1
Filed Apr 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. $633K
15,000 sh across 2 lots
Exec Mar 2
Filed Mar 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. $462K
14,043 sh × $32.87
Exec Feb 2
Filed Feb 4 · 5:30 PM ET